- Prior authorization (PA) is a payer's requirement that your prescriber justify certain drugs before the plan will pay, most often for pricey brand or specialty drugs.
- Approval hinges on documentation: your diagnosis, what you have already tried and why it failed, objective clinical data, and a clear medical-necessity statement.
- If you are denied, you can appeal — many denials are overturned — through a first-level appeal, an independent external review, and, if needed, your state insurance department.
- Electronic prior authorization (ePA) can turn a multi-day wait into hours by submitting the request from the doctor's EHR.
- The CMS-0057-F final rule requires affected plans to decide expedited requests within 72 hours and standard requests within 7 calendar days, with process and denial-reason requirements starting January 1, 2026 and API requirements by January 1, 2027.
- Coverage rules vary by plan, so check your specific formulary and PA criteria — and stay on top of the submission rather than waiting passively.
You need a medication. Your doctor prescribes it. And then your pharmacy tells you it is not covered without extra paperwork. Welcome to prior authorization for medication — a process that touches a large share of prescription and medical claims in the United States. According to the American Medical Association, prior authorization is widespread and a frequent source of care delays. While it can feel like an obstacle, understanding how it works and what your doctor needs to submit can mean the difference between days and weeks of waiting. This article is general education, not medical or legal advice — check your own plan’s rules.
Why Medications Require Prior Authorization
Prior authorization is a cost-control tool used by health insurers and pharmacy benefit managers (PBMs). Before your plan agrees to pay for certain drugs, it requires your prescribing doctor to submit evidence that the medication is medically necessary and that less expensive alternatives are not appropriate.
Not every medication requires prior authorization. The drugs most commonly flagged include new brand-name medications that have generic alternatives, specialty drugs costing thousands per month, medications with significant safety or abuse potential, and drugs where clinical guidelines recommend trying a first-line therapy before a more expensive option.
Your PBM — whether it is Express Scripts, CVS Caremark, or OptumRx — establishes the prior authorization criteria based on clinical evidence, FDA labeling, and cost. The criteria spell out exactly what documentation the prescriber must provide.
Step-by-Step: How Prior Authorization Works
The process follows a predictable path, though timelines vary by plan and urgency level.
1. Prescription submission and rejection. You bring your prescription to the pharmacy. The pharmacist submits the claim electronically, and the PBM’s system returns a rejection code indicating prior authorization is required. The pharmacist notifies you and may provide a reference number.
2. Prescriber receives notification. The PBM sends a notification to your doctor’s office — electronically or by fax — with the PA form and coverage criteria. Some PBMs offer electronic PA (ePA) that lets the prescriber submit the request in real time during the visit.
3. Documentation submission. Your doctor’s office completes the PA form, including your diagnosis, relevant lab results, medications you have previously tried (and why they did not work), and a statement of medical necessity. Thorough documentation here is critical; incomplete forms are the leading cause of delays and denials.
4. Payer/PBM review. A clinical pharmacist or medical director reviews the submission against the plan’s coverage criteria. Under the new federal rule described below, affected plans must decide standard requests within 7 calendar days and expedited (urgent) requests within 72 hours; many commercial plans already act faster.
5. Decision notification. The plan notifies both your doctor and you of the decision: approved, denied, or approved with modifications (such as a different dose or quantity). Approvals are typically valid for 6 to 12 months, after which a renewal request is required. If denied, the plan must give a specific reason.
What the CMS-0057-F Rule Changes in 2026-2027
The biggest recent development is the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), which tightens timelines and transparency for affected government-related plans:
- Faster decisions. Impacted payers must send decisions within 72 hours for expedited (urgent) requests and 7 calendar days for standard (non-urgent) requests. (The decision-timeframe requirement applies to Medicare Advantage, Medicaid and CHIP fee-for-service and managed care plans; QHP issuers on the Federally Facilitated Exchanges are excluded from that specific timeframe piece.)
- Specific denial reasons. Beginning in 2026, affected payers must provide a specific reason for a denied prior authorization, regardless of how the decision is sent — which makes appeals easier to target.
- Public metrics. Payers must publicly report certain PA metrics annually on their websites, with initial reporting due by March 31, 2026.
- Effective dates. The operational and process requirements (including denial reasons and metrics) take effect January 1, 2026, while the required Prior Authorization API for electronic data exchange must be implemented by January 1, 2027.
Two caveats worth knowing: this federal rule focuses on medical-item and service prior authorization for those government-related plans, and drugs covered under a pharmacy benefit can follow separate rules. Commercial/employer plans are not all bound by CMS-0057-F, though many are adopting similar timelines. Always confirm what applies to your specific coverage.
How Prior Authorization Relates to Step Therapy
Prior authorization often works hand in hand with step therapy, sometimes called “fail first.” Step therapy requires you to try one or more preferred (usually cheaper) drugs before the plan will approve a costlier one. When you request the pricier drug, prior authorization is the mechanism used to check whether you have completed — or have a valid reason to skip — those required steps. If you have already failed the first-line options, or cannot take them for medical reasons, documenting that clearly in the PA request is often what unlocks approval.
What Documentation Strengthens a Prior Authorization Request
The strength of the submission directly correlates with the likelihood of approval. Here is what makes a prior authorization for medication request compelling:
Complete treatment history. List every medication you have tried for the condition, with dosages and durations, and document why each was discontinued — lack of effectiveness, side effects, allergic reactions, or interactions. PBMs want to see that cheaper alternatives were given a fair trial.
Objective clinical data. Lab results, imaging, and clinical measurements strengthen the case. For a biologic requested for rheumatoid arthritis, include disease-activity scores, inflammatory markers (CRP, ESR), and imaging. For a specialty cancer drug, include pathology and genetic testing results.
Clear medical-necessity statement. Your doctor should explain why this specific medication — not an alternative — is right for your situation. Detailed clinical reasoning beats generic statements like “patient needs this drug.”
Supporting clinical literature. For off-label uses or newer medications, peer-reviewed studies from PubMed or professional-society guidelines can bolster the request. Citing a recommendation from a body like the American College of Rheumatology or the National Comprehensive Cancer Network helps.
What to Do If Prior Authorization Is Denied
A denial is not the end. According to AMA survey data, a substantial share of prior authorization denials are overturned on appeal. You have both the right and the tools to fight a denial, and federal appeal rights under the ACA apply to most plans.
Understand the denial reason. The plan must provide a specific written explanation. Common reasons include insufficient documentation, failure to try a required step-therapy drug, a diagnosis not meeting coverage criteria, or the medication being excluded from the formulary.
First-level (internal) appeal. Your doctor submits additional clinical documentation addressing the specific denial reason. If the denial was based on missing information, supplying it may resolve the issue quickly. If it was based on step therapy, documenting why the required first-line drugs are inappropriate for you is essential. Consider requesting a peer-to-peer review, where your prescriber speaks directly with the plan’s reviewing physician.
Independent external review. If the internal appeal is denied, most plans must offer an external review by an independent third party not affiliated with your insurer or PBM. External review is particularly effective for complex cases where the treating specialist has strong clinical justification. Under the ACA, the external reviewer’s decision is generally binding on the plan.
State insurance department. If you believe the denial violates state law or your plan’s terms, you can file a complaint with your state’s department of insurance. Some states have specific protections for certain prior authorization or step-therapy denials.
Electronic Prior Authorization: A Faster Path
Traditional prior authorization involves faxed forms, phone calls, and multi-day waits. Electronic prior authorization (ePA) is changing that. Through ePA, prescribers can submit PA requests directly from their electronic health record (EHR) during the visit; the system may evaluate the request quickly, sometimes returning an approval before the patient leaves the office. The federal push toward standardized electronic PA — including the CMS-0057-F Prior Authorization API required by 2027 — is designed to make this the norm rather than the exception.
Not all medications or plans are integrated into ePA systems yet. Ask your doctor’s office whether they can submit electronically; if so, the process may resolve in hours rather than days.
Prior Authorization for Specific Medication Categories
GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound): These high-demand drugs almost universally require prior authorization. Plans typically require documentation of a diabetes or obesity diagnosis, failed lifestyle interventions, and sometimes BMI criteria. Coverage varies significantly — see our guide on Medicare coverage of Wegovy for program-specific details.
Biologics: Nearly all biologics require PA, and plans typically mandate step therapy through conventional treatments first. Biosimilars — FDA-approved copies of biologic drugs — may face fewer PA hurdles than reference biologics.
Controlled substances: Opioids and benzodiazepines frequently require PA, especially above recommended thresholds. Documentation should include a pain-management plan, a risk assessment, and evidence of monitoring such as prescription drug monitoring program checks.
Specialty medications: Drugs dispensed through specialty pharmacies like OptumRx specialty pharmacy almost always require prior authorization because of their high cost and complex clinical profiles.
Frequently Asked Questions
How long does prior authorization for medication take?
It varies by plan and urgency. Under CMS-0057-F, affected plans must decide expedited (urgent) requests within 72 hours and standard requests within 7 calendar days; many plans act faster, and ePA can produce a decision in hours. Medicare Part D drug requests have their own timelines. Delays most commonly result from incomplete submissions or difficulty reaching the prescriber.
Can I get a temporary supply while waiting for prior authorization?
Often, yes. Many plans allow a one-time emergency or transition supply to bridge the gap while a PA is pending — ask your pharmacist about an emergency-supply override. Medicare Part D plans are generally required to offer a temporary transition supply in qualifying situations.
Does prior authorization apply to generic medications?
Rarely. Most generics are on the formulary without PA. Some may require it if used for off-label indications, in quantities above standard limits, or when newly on the market without an established utilization history.
Who is responsible for submitting the prior authorization?
Your prescribing doctor’s office submits the PA request and supporting documentation. You can help by providing your insurance information, confirming the request was submitted, and checking status with the plan or PBM.
What is a peer-to-peer review?
It is a phone conversation between your prescriber and a physician reviewer at the plan, used to discuss the clinical justification directly. Requesting a peer-to-peer is often a productive step when a request is denied for a judgment-based reason rather than missing paperwork.
Taking Control of the Process
Waiting for prior authorization for medication is frustrating, but passivity makes it worse. Ask your doctor to check PA requirements before prescribing. If PA is needed, confirm the submission within 24 hours. Follow up with both your doctor’s office and the plan every couple of days until you have a decision. And if you are denied, appeal — the data support persistence, and the specific denial reason plans must now provide gives you a clear target. Always verify what your particular plan requires, since formularies and criteria change.
For more on how prior authorization fits into the broader benefits landscape, including PBM reform efforts that aim to streamline it, visit our healthcare policy guide.
This article is general education, not medical, legal, or insurance advice. Prior authorization rules, timelines, and formularies vary by plan and change over time; the CMS-0057-F timelines described here apply to specific government-related plans. Confirm the requirements and deadlines for your own coverage with your plan, PBM, and prescriber, and do not delay needed care while a request is pending.
Sources
- CMS — Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet: 72-hour expedited and 7-calendar-day standard decision timeframes; covered payers (Medicare Advantage, Medicaid/CHIP FFS and managed care, QHP issuers on the FFEs, with the timeframe requirement excluding FFE QHP issuers); specific denial reasons and public PA metrics beginning 2026 (initial metrics by March 31, 2026); Prior Authorization API by January 1, 2027
- HealthCare.gov / CMS — internal appeal and independent external review rights under the Affordable Care Act
- American Medical Association (AMA) — prior authorization prevalence and that many denials are overturned on appeal
- MedlinePlus (U.S. National Library of Medicine) — general guidance on prescription coverage and working with your prescriber and pharmacy